Streetbeat News

Products Services

CATX

Perspective Therapeutics has entered into a patent license agreement with Mayo Clinic for the PSMA Alpha-PET DoubLET platform technology, which is used for imaging and targeted therapy in PSMA-expressing cancers, primarily prostate cancer. The technology involves a double chelator design using isotopes 64/67Cu and 203/212Pb for radiopharmaceutical therapy (RPT).

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 1:18 pm

QCOM

SSNLF

Samsung Electronics Co Ltd. (OTCPK: SSNLF) is offering a pre-order deal on its upcoming Galaxy S24, allowing customers to save up to $1,020. The deal includes a $50 credit for reservations and up to $970 in trade-in discounts. The Galaxy S24, featuring AI-powered capabilities and expected to run on Qualcomm Inc.'s (NASDAQ: QCOM) Snapdragon 8 Gen 3 chipset, will be launched at Samsung's 'Unpacked' event on January 17.

Portfolio Pulse from Rounak Jain

January 05, 2024 | 1:17 pm

ALUR

Allurion Technologies conducted research showing that nearly 90% of healthcare professionals (HCPs) consider the Allurion Program an ideal first-line treatment for achieving over 10% body weight loss quickly and sustainably. The study involved 172 HCPs and 1663 patients across 64 countries, assessing the impact of growing interest in anti-obesity medications on the awareness and uptake of the Allurion Program.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 1:16 pm

SPRO

Spero Therapeutics has announced that it will soon provide Phase 2a topline proof of concept data for its SPR720 program. Additionally, the company has begun dosing in its PIVOT-PO Phase 3 trial. Spero is also set to receive $95 million in milestone payments as part of a licensing agreement.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 1:11 pm

CMPX

Compass Therapeutics, Inc. (CMPX) provided a corporate update, detailing progress in their clinical trials for various cancer treatments. The company expects to report top-line data from the COMPANION-002 and COMPANION-003 studies in the second half of 2024 and mid-year 2024, respectively. CTX-471 showed promising results, with one patient achieving a complete response. The company also plans to dose the first patient with CTX-8371 in Q1 2024. Leadership changes include Vered Bisker-Leib becoming CEO and Thomas Schuetz transitioning to President of R&D. Compass ended 2023 with $152 million in cash, expected to last until mid-2026.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 1:11 pm

NFLX

Netflix Inc. (NASDAQ:NFLX) is exploring ways to monetize its gaming division, considering options such as in-app purchases, charging for premium games, and extending gaming access to ad-tier subscribers. This marks a strategic shift from its previous stance of offering games without monetization to focus on the gaming experience. Despite concerns from some executives and investors about resource allocation, Netflix's gaming has seen growth, with a significant increase in game downloads and plans to enhance its gaming budget for higher quality games.

Portfolio Pulse from Benzinga Neuro

January 05, 2024 | 1:11 pm

IRTC

iRhythm Technologies, Inc. announced the publication of the CAMELOT study results in the American Heart Journal, which demonstrated a higher clinical diagnostic yield and lower odds of restarting with their Zio long-term continuous monitoring (LTCM) product. The findings suggest that Zio LTCM may offer significant benefits in diagnosing heart conditions compared to other methods.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 1:10 pm

GM

General Motors Co (NYSE:GM) is transitioning its EV lineup after discontinuing the Chevrolet Bolt EV and EUV, which represented over 80% of its 75,000 EVs sold in the U.S. in 2023. The Lake Orion plant, previously producing the Bolt, is being retooled for electric trucks like the Chevrolet Silverado EV and GMC Sierra EV, with production starting in late 2025. GM's short-term EV delivery targets are unclear, but it aims to go all-electric by 2035.

Portfolio Pulse from Anan Ashraf

January 05, 2024 | 1:09 pm

INSM

Insmed Incorporated (NASDAQ:INSM) provided a business update at the 42nd Annual J.P. Morgan Healthcare Conference, forecasting 2024 global ARIKAYCE revenues of $340M-$360M, exceeding FY23 guidance with unaudited sales of ~$305.2M. The company expects significant growth and transformative developments in 2024, including topline data from Phase 3 ASPEN study of Brensocatib and Phase 2 study of TPIP. Insmed's early-stage research comprises over 30 pre-clinical programs, with less than 20% of overall spend.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 1:06 pm

COYA

Coya Therapeutics announced successful pre-IND and Type C meetings with the FDA regarding the development of COYA 302, a treatment for Amyotrophic Lateral Sclerosis (ALS). These meetings are critical steps in advancing the drug towards clinical trials and potential approval.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 1:05 pm